4.6 Review

Nanopharmaceutical-based regenerative medicine: a promising therapeutic strategy for spinal cord injury

Journal

JOURNAL OF MATERIALS CHEMISTRY B
Volume 9, Issue 10, Pages 2367-2383

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/d0tb02740e

Keywords

-

Funding

  1. National Natural Science Foundation of China [32071359, 31771058, 11421202, 11827803, 61227902, 11120101001]
  2. National Key Technology RD Program [2016YFC1100704, 2016YFC1101101]
  3. International Joint Research Center of Aerospace Biotechnology and Medical Engineering from the Ministry of Science and Technology of China
  4. 111 Project [B13003]
  5. Research Fund for the Doctoral Program of Higher Education of China [20131102130004]
  6. Fundamental Research Funds for the Central Universities

Ask authors/readers for more resources

Spinal cord injury (SCI) results in loss of perceptive and athletic function, lacking effective treatment methods and facing limitations in drug therapy. Nanopharmaceuticals show great potential in SCI treatment, with the ability to enhance therapeutic effects and reduce side effects.
Spinal cord injury (SCI) is a neurological disorder that can lead to loss of perceptive and athletic function due to the severe nerve damage. To date, pieces of evidence detailing the precise pathological mechanisms in SCI are still unclear. Therefore, drug therapy cannot effectively alleviate the SCI symptoms and faces the limitations of systemic administration with large side effects. Thus, the development of SCI treatment strategies is urgent and valuable. Due to the application of nanotechnology in pharmaceutical research, nanopharmaceutical-based regenerative medicine will bring colossal development space for clinical medicine. These nanopharmaceuticals (i.e. nanocrystalline drugs and nanocarrier drugs) are designed using different types of materials or bioactive molecules, so as to improve the therapeutic effects, reduce side effects, and subtly deliver drugs, etc. Currently, an increasing number of nanopharmaceutical products have been approved by drug regulatory agencies, which has also prompted more researchers to focus on the potential treatment strategies of SCI. Therefore, the purpose of this review is to summarize and elaborate the research progress as well as the challenges and future of nanopharmaceuticals in the treatment of SCI, aiming to promote further research of nanopharmaceuticals in SCI.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available